Last reviewed · How we verify
NCT02235051
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
NA trial testing exercise intervention in Cancer Survivor in 50 participants. Completed in 3 June 2022.
19 December 2016
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 50 |
| Start date | 7 September 2014 |
| Primary completion | 19 December 2016 |
| Estimated completion | 3 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- exercise intervention
- laboratory biomarker analysis — full drug profile →
- questionnaire administration
- quality-of-life assessment
Conditions studied
- Cancer Survivor — all drugs for Cancer Survivor →
- Estrogen Receptor-positive Breast Cancer — all drugs for Estrogen Receptor-positive Breast Cancer →
- Stage IA Breast Cancer — all drugs for Stage IA Breast Cancer →
- Stage IB Breast Cancer — all drugs for Stage IB Breast Cancer →
Sponsor
City of Hope Medical Center
Who can join
56 and older, female only, with Cancer Survivor or Estrogen Receptor-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized pilot trial studies how well an exercise intervention works in preventing breast cancer from coming back in postmenopausal breast cancer survivors. Regular exercise may be able to train the body to repair deoxyribonucleic acid (DNA) more efficiently and to respond to inflammation more proficiently, helping to prevent primary and recurrent breast cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Physical activity for women with breast cancer after adjuvant therapy.
Lahart IM, Metsios GS, Nevill AM, Carmichael AR. · · 2018 · cited 161× · PMID 29376559 · DOI 10.1002/14651858.cd011292.pub2 -
Advances in Diet and Physical Activity in Breast Cancer Prevention and Treatment.
Khalifa A, Guijarro A, Nencioni A. · · 2024 · cited 17× · PMID 39064705 · DOI 10.3390/nu16142262 -
Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians.
Ruggieri L, Moretti A, Berardi R, Cona MS, et al · · 2023 · cited 8× · PMID 36902406 · DOI 10.3390/ijms24054974
Verify or expand the search:
- PubMed search for NCT02235051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of exercise intervention
Trials testing the same drug.
- NCT06633575 — Profile and Regulatory Network of Exercise in Improving Metabolic Phenotypes of Patients With Prediabetes · NA · recruiting
- NCT06633653 — Mechanism Study of Metabolic Response and Health Benefit Induced by Exercise · NA · not yet recruiting
- NCT06656377 — Optimization of Exercise Protocol for Prediabetic Population in Postprandial State · NA · completed
- NCT04507789 — Exercise Therapy During Radiotherapy · NA · unknown
- NCT01909440 — Resistance Training and Protein Supplementation for Prostate Cancer Survivors · NA · completed
Other recruiting trials for Cancer Survivor
Currently open trials in the same condition.
- NCT06894849 — Text -Based Depression Screening Among Cancer Survivors · NA · recruiting
- NCT06868524 — Leading Healthy Eating and Activity Promotion Program · NA · recruiting
- NCT06574009 — Better Options for Chronic Cancer Pain · Phase 4 · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT06814977 — An Acupuncture Study for Cancer Survivors With Joint Pain · NA · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02235051 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 21 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02235051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing